A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale

Background: The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD. Aim and Objectives: To assess the effectiveness and adverse effect profile of tofacitinib in recalcitrant, moderate-to-severe AD patients...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kabir Sardana, Savitha Sharath, Sumitra Kumari Meena, Ananta Khurana, Bhawuk Dhir
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wolters Kluwer Medknow Publications 2025-05-01
Edice:	Indian Dermatology Online Journal
Témata:	atopic dermatitis cyclosporine dupilumab easi efficacy jak inhibitors th1 th2 th17 th22 tofacitinib
On-line přístup:	https://journals.lww.com/10.4103/idoj.idoj_665_24
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!